A fresh daily pill from Eli Lilly is showing promise as a more effective oral option for weight loss, according to results from a recent Phase 3 clinical trial. The drug, called orforglipron, demonstrated greater weight loss in patients with type 2 diabetes compared to oral semaglutide, currently the only GLP-1 medication for diabetes available in pill form in the United States. This development could offer a significant advancement for individuals seeking non-injection alternatives for managing weight and blood sugar levels, a growing area of focus in healthcare.
Orforglipron works by targeting the same GLP-1 receptors as semaglutide, a class of drugs known to lower blood sugar, slow digestion, and suppress appetite. Unlike existing oral semaglutide tablets, orforglipron does not require patients to take it on an empty stomach, potentially improving adherence and convenience. The findings, published in The Lancet, arrive as demand for weight-loss medications continues to surge, fueled by growing rates of obesity and related health conditions.
Trial Results: Orforglipron Outperforms Oral Semaglutide
The Achieve-3 trial, funded by Eli Lilly, involved over 1,500 adults with type 2 diabetes across Argentina, China, Japan, Mexico, and the US. Participants were assigned to receive either 12mg or 36mg of orforglipron, or 7mg or 14mg of oral semaglutide, over a year-long period. The results showed that patients taking orforglipron experienced an average weight loss of 6-8%, compared to 4-5% in the semaglutide group. Those on orforglipron as well exhibited lower average blood sugar levels at the trial’s conclusion.
While the weight loss results are encouraging, the trial also revealed a higher rate of discontinuation among participants taking orforglipron. Approximately 9-10% of individuals stopped treatment due to side effects, primarily gastrointestinal issues, compared to 4-5% in the semaglutide groups. This highlights a potential trade-off between efficacy and tolerability that will need further investigation.
The Promise of Oral GLP-1s and Current Market Landscape
Experts believe that oral GLP-1 medications could be transformative due to their ease of apply and potential cost-effectiveness compared to injectable options like Ozempic and Wegovy. Currently, Rybelsus is the only GLP-1 medication available in pill form in the US, used for treating diabetes. Novo Nordisk recently launched a pill version of Wegovy, but oral semaglutide has generally been shown to be less effective for weight loss than its injectable counterparts, or tirzepatide injections like Mounjaro. The potential for a more potent oral option like orforglipron could significantly expand access to these medications.
“The more effective oral medicines we have to help people with type 2 diabetes lose weight and keep it off, the better,” said Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, as reported in the source material. He added that a holistic approach targeting weight, blood sugar, and cardiovascular risk simultaneously is likely to yield the greatest benefits for patients.
Concerns and Next Steps
Despite the positive findings, some experts caution that longer-term data is needed to fully assess the safety, cardiovascular outcomes, and sustained effectiveness of orforglipron. Dr. Marie Spreckley, of the MRC epidemiology unit at the University of Cambridge, emphasized that the one-year duration of the trial leaves significant questions unanswered. The higher discontinuation rate due to gastrointestinal side effects also warrants careful consideration for real-world application.
Tam Fry, chair of the National Obesity Forum, noted the potential for orforglipron to become a treatment of choice for obese individuals with diabetes, but stressed the need for stricter controls on its availability to prevent misuse, referencing concerns about life-threatening usage of similar medications, as reported by The Guardian.
Orforglipron is currently under review by regulatory bodies in the US, UK, and Europe. Eli Lilly has not yet announced a specific timeline for potential approval and market launch. Investors are closely watching the progress of orforglipron, as evidenced by recent news from December 2025 indicating positive topline results from the ATTAIN-MAINTAIN trial, which evaluated the drug’s ability to help patients maintain weight loss after initial treatment. Eli Lilly’s investor relations website provides further details on this trial.
recent reports suggest that orforglipron has shown promising results in a head-to-head trial against Wegovy’s pill form, potentially surpassing its effectiveness in a diabetes trial, according to pharmaphorum.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The coming months will be crucial as Eli Lilly awaits regulatory decisions and prepares for potential market entry. The FDA’s review will be a key checkpoint, and further data on long-term safety and efficacy will be closely scrutinized. We will continue to follow this story as it develops.
What are your thoughts on the potential of oral weight-loss medications? Share your comments below, and please share this article with anyone who might find it informative.
